Amzell Sees Benefit From High-Strength Topical Diclofenac
Diclofenac 3.06% Gel Shows Promise For Knee Osteoarthritis
Amzell has revealed trial results indicating that its diclofenac 3.06% gel formulation is effective for treating knee osteoarthritis symptoms.
You may also be interested in...
Virpax Pharmaceuticals and partner MedPharm say they have made progress towards filing through the US 505(b)(2) hybrid pathway a diclofenac spray for treating osteoarthritis of the knee.
The US marketplace for biosimilars is accelerating faster than the EU at a similar point in its existence, based on approval rates, Amgen has observed in a preview of its 2022 trends in biosimilars report that also offers new data on pricing and uptake.
Glenmark has moved to bolster its over-the-counter business in the US by acquiring a portfolio of approved generic OTC products from Wockhardt.